TELEFLEX INC (TFX) SEC Filings

TELEFLEX INC (TFX) filed an initial statement of beneficial ownership on Form 3 for Sean Salmon, who is identified as a director of the company. The filing reports no transactions, no derivative positions, and no reportable share holdings at this time.

Teleflex Incorporated (TFX) reported that its Board of Directors increased its size from eight to nine members and elected Sean M. Salmon to the Board effective September 8, 2026. He was also appointed to the Board’s Growth and Operating Committee, which supports the company’s strategic transformation and operational initiatives.

Mr. Salmon brings more than 30 years of global leadership experience in medical devices and pharmaceuticals, including over 20 years at Medtronic plc, where he most recently led its Cardiovascular Portfolio, a global business with fiscal 2025 revenue of approximately $12.5 billion. Following his appointment, the Teleflex Board consists of nine directors, eight of whom are independent, and one third of the Board has been refreshed in 2026. Teleflex states that his experience in capital allocation, portfolio strategy and operational execution is expected to complement the Board’s existing capabilities.

TELEFLEX INC (TFX) is reported to have 4,343,764 shares of its common stock, or 10.3% of the class, beneficially owned or deemed beneficially owned by Janus Henderson Group Ltd. and its affiliated asset managers. All 4,343,764 shares are held with shared voting and dispositive power; none are held with sole power. These shares are owned in client accounts of various Janus Henderson-managed portfolios, which retain the right to receive all dividends and sale proceeds. Within these, Janus Henderson Enterprise Fund is reported with 2,885,870 shares, or 6.8% of Teleflex’s common stock.

T. Rowe Price Investment Management, Inc. reports an institutional ownership position in Teleflex Inc. common stock. The firm reports beneficial ownership of 3,194,710 shares of common stock, representing 7.2% of the class. It has sole voting power over 3,183,336 shares and sole dispositive power over 3,194,710 shares, with no shared voting or dispositive power reported. T. Rowe Price Investment Management states that this filing should not be construed as an admission that it is the beneficial owner of these securities, and that such beneficial ownership is expressly denied.

Teleflex Incorporated entered into an accelerated share repurchase program with Truist Bank to repurchase $250 million of its common stock, par value $1.00 per share. This transaction is being completed under Teleflex’s previously announced $1 billion share repurchase program.

On August 10, 2026, Teleflex will pay the $250 million repurchase price and receive an initial delivery of shares valued at 80% of that amount, based on the August 6, 2026 closing price. The final share count will be determined using volume-weighted average prices during the ASR term, less a discount and subject to adjustments. At final settlement, Teleflex may receive additional shares or may deliver shares or cash, at its option. The ASR is scheduled to terminate in the fourth quarter of 2026 and will be funded with proceeds from the sale of Teleflex’s Original Equipment Manufacturing and Development Services business.

Teleflex Incorporated reported strong top-line growth but weaker profitability for the quarter ended June 30, 2026. Net revenues from continuing operations were $570.3 million, up 28.9% from $442.5 million, driven largely by $99.0 million of sales from the acquired BIOTRONIK Vascular Intervention business and higher volumes of existing products.

Gross margin declined to 58.2% from 60.1% as tariffs enacted in 2025, the lower-margin profile of the VI Business, and related intangible amortization pressured costs. Income from continuing operations was $41.8 million versus $68.2 million a year earlier, while net income, including discontinued operations, was $99.7 million compared with $122.6 million.

Teleflex is executing a major portfolio reshaping through “Strategic Divestitures” of its OEM, Acute Care and Interventional Urology businesses for a combined $2.0 billion in cash. On August 3, 2026, it completed the OEM sale, receiving $1.5 billion of net proceeds and expects an approximately $1.0 billion pre-tax gain, using part of the cash to repay the $700 million term A-2 loan facility.

Teleflex Incorporated reported second-quarter 2026 continuing-operations revenue of $570.3 million, up 28.9% year over year and up 4.7% on a pro forma adjusted constant currency basis. GAAP diluted EPS from continuing operations was $0.96, down from $1.54, while adjusted diluted EPS edged up to $1.76 from $1.73, reflecting margin pressure but slightly higher underlying earnings.

The company completed the sale of its OEM business to Montagu and Kohlberg for $1.5 billion in cash, estimating about $1.25 billion in after-tax proceeds and using this to pay off a $700 million term loan and support share repurchases. In the second quarter it repurchased 1.9 million shares for $250 million and plans a further $250 million accelerated share repurchase under a $1 billion authorization. Teleflex cut 2026 GAAP revenue growth guidance to 13.40%–14.40% and pro forma adjusted constant currency growth to 3.50%–4.50%, but raised adjusted EPS guidance to $6.90–$7.20, targeting about 19% adjusted operating margin. The company also highlighted innovation milestones, including FDA BLA approval of EZPLAZ Freeze Dried Plasma, the first freeze-dried plasma licensed by the FDA, and continued clinical progress for its Freesolve resorbable magnesium scaffold platform.

Teleflex Incorporated provides unaudited pro forma financial information reflecting the completed sale of its Original Equipment Manufacturing and Development Services business, which generated net cash proceeds of $1.5 billion and estimated after-tax net cash proceeds of $1,244.9 million.

The pro forma balance sheet as of March 31, 2026 removes OEM assets and liabilities and applies these proceeds, including an assumed $700.0 million repayment of the term A‑2 loan facility. On this basis, total assets are 6,838,584 thousand, total liabilities 3,013,084 thousand and shareholders’ equity 3,825,500 thousand.

For the three months ended March 31, 2026, income from continuing operations shifts from a reported loss of 4,838 thousand to pro forma income of 1,905 thousand, or $0.04 diluted EPS. For 2025, income from continuing operations increases from 58,530 thousand reported to 86,873 thousand pro forma, with diluted EPS of $1.94. These pro formas exclude the pending Acute Care and Interventional Urology divestiture.

Teleflex Incorporated completed the previously announced divestiture of its Original Equipment Manufacturing and Development Services business to Lotus US Bidco Inc. on August 3, 2026, for $1.5 billion in cash, subject to purchase price adjustments under the equity purchase agreement.

Teleflex estimates after‑tax proceeds of approximately $1.25 billion and states an intent to use the net proceeds to reduce debt by $800 million and help complete its $1 billion share repurchase authorization. At closing, the parties also entered a transition services agreement, a development and manufacturing agreement and a long‑term supply agreement to support ongoing product development and supply. Pro forma financial information reflecting the divestiture will be filed by amendment within four business days of closing, and Teleflex plans to provide updated 2026 financial guidance when it reports second‑quarter results on August 6, 2026.